Mouse models for pre-clinical drug testing in leukemia.

Area of Science:

• Oncology
• Pharmacology
• Translational Medicine

Background:

• Modern leukemia treatment requires novel drugs targeting leukemic cells to improve remission and reduce toxicity.
• The transition of potential drugs from laboratory research to clinical application (bench to bedside) is hindered by high failure rates in early clinical trials due to toxicity.
• Existing preclinical models often fail to accurately predict clinical outcomes, leading to drug development attrition.

Purpose of the Study:

• To review the development of murine models for targeted therapy research in childhood leukemia.
• To address the low attrition rate of complex targeted therapies, including small molecules and cell therapies.
• To highlight the need for more sophisticated murine models that closely mimic human disease phenotypes.

Main Methods:

• Discussion of murine model generation for targeted therapy development.
• Analysis of xenograft models for efficacy testing.
• Evaluation of genetically engineered mouse models (GEMMs) for toxicity assessment.

Main Results:

• Complex therapeutic approaches necessitate the development of more complex murine models to accurately recapitulate human phenotypes.
• Combining xenograft and GEMMs offers a comprehensive approach for preclinical testing.
• This integrated strategy is anticipated to enhance the clinical approval rate of novel therapeutic compounds.

Conclusions:

• The development and application of advanced murine models are critical for improving the preclinical evaluation of novel leukemia therapies.
• A combined approach using xenograft and GEMMs for efficacy and toxicity testing, respectively, is proposed.
• This strategy is expected to increase the success rate of novel targeted therapies in clinical trials and contribute to improved patient outcomes.